Wim Schuermans

Dr. Wim Schuermans

Ziekenhuis Geel, Geel, Belgium
orcid

Research Focus & Metrics

Academic Career Length

13Years (2014-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
14 June 2022 in Viruses
Verified
Journal Article
Open access
PDF file
LCLize Cuypers
Lize Cuypers
JBJannes Bode
Jannes Bode
KBKurt Beuselinck
Kurt Beuselinck
LLLies Laenen
Lies Laenen
KDKlaas Dewaele
Klaas Dewaele
EAEmmanuel André
Emmanuel André
From early 2020, a high demand for SARS-CoV-2 tests was driven by several testing indications, including asymptomatic cases, resulting in the massive roll-out of PCR assays to combat the pandemic. Considering the dynamic of viral shedding during the course of infection, the demand to report cycle threshold (Ct) values rapidly emerged. As Ct values can be affected by a number of factors, we considered that harmonization of semi-quantitative PCR results across laboratories would avoid potential divergent interpretations, particularly in the absence of clinical or serological information. A proposal to harmonize reporting of test results was drafted by the National Reference Centre (NRC) UZ/KU Leuven, distinguishing four categories of positivity based on RNA copies/mL. Pre-quantified control material was shipped to 124 laboratories with instructions to setup a standard curve to define thresholds per assay. For each assay, the mean Ct value and corresponding standard deviation was calculated per target gene, for the three concentrations (107, 105 and 103 copies/mL) that determine the classification. The results of 17 assays are summarized. This harmonization effort allowed to ensure that all Belgian laboratories would report positive PCR results in the same semi-quantitative manner to clinicians and to the national database which feeds contact tracing interventions.

Verified
Journal Article
Open access
PDF file
Wim SchuermansWim Schuermans
Wim Schuermans
HOHans Orlent
Hans Orlent
IDIsabelle Desombere
Isabelle Desombere
PDPatrick Descheemaeker
Patrick Descheemaeker
HVHans Van Vlierberghe
Hans Van Vlierberghe
EPElizaveta Padalko
Elizaveta Padalko
As different hepatitis C virus (HCV) genotypes respond differently to initiated therapy, correct HCV genotyping is essential. A potential risk for misclassification of the intergenotypic HCV circulating recombinant form (CRF) 2k/1b strains exists, depending on the genotyping method used. The aim was to investigate the differences in HCV genotyping methods with regard to CRF 2k/1b and to gain insight in the prevalence of the CRF 2k/1b. Genotyping results by Versant HCV Genotype Assay were compared with nonstructural protein 5B (NS5B) sequencing. In total, from November 2001 until March 2015, 3296 serum samples were analyzed by Versant HCV Genotype Assay. As misclassified CRF is harbored among HCV genotype 2, we further focused our search on 142 (4.3%) samples positive for HCV genotype 2. On 116 (81.7%) retrieved samples, the NS5B sequencing was performed. Twelve out of the 116 retrieved samples (10.3%) were classified as CRF 2k/1b by sequencing of the NS5B region. Ten of these 12 samples were originally misclassified as genotype 2a or 2c, while 2 of them were misclassified as genotype 2. Our results show that the current prevalence of CRF 2k/1b is underestimated. The importance of correct HCV genotyping is emphasized, considering the tailored choice of treatment regimen and overall prognosis.

8 April 2014 in International Journal of Laboratory Hematology
Verified
Journal Article
Closed access
PDF file
CIC. Indevuyst
C. Indevuyst
Wim SchuermansWim Schuermans
Wim Schuermans
EBE. Bailleul
E. Bailleul
PMP. Meeus
P. Meeus

27 June 2017 in Mycopathologia
Verified
Journal Article
Closed access
PDF file
Wim SchuermansWim Schuermans
Wim Schuermans
KHK. Hoet
K. Hoet
LSL. Stessens
L. Stessens
JMJ. Meeuwissen
J. Meeuwissen
AVA. Vandepitte
A. Vandepitte
GCG. Coppens
G. Coppens

1 September 2014
Verified
Journal Article
Closed access
Wim SchuermansWim Schuermans
Wim Schuermans
SMS Mulliez
S Mulliez
EPE Padalko
E Padalko
MRM Reynders
M Reynders
ABA Boel
A Boel
HBH De Beenhouwer
H De Beenhouwer

20 August 2016 in Journal of Clinical Virology
Verified
Journal Article
Closed access
CBC. Van Den Borre
C. Van Den Borre
Wim SchuermansWim Schuermans
Wim Schuermans
HVH. Van Vlierberghe
H. Van Vlierberghe
AGAnja Geerts
Anja Geerts
Xavier VerhelstXavier Verhelst
Xavier Verhelst
EPElizaveta Padalko
Elizaveta Padalko